Galectin Therapeutics Still A Favorite Pick Of H.C. Wainwright Analysts By: Benzinga via Benzinga September 28, 2015 at 14:11 PM EDT H.C. Wainwright reiterated a Buy rating and $7.00 price target on shares of Galectin Therapeutics Inc (NASDAQ: GALT) on ... Read More >> Related Stocks: Conatus Pharmaceutic Galectin Therapeutic